Table 3.
Matrix | Mycotoxin | Spiked Level (ng mL−1) | Recovery (Mean ± SD %) | ||
---|---|---|---|---|---|
Short-Term Stability a | Freeze-Thaw Stability b | Long-Term Stability c | |||
Urine | OTA | 1 | 98.3 ± 8.1 | 97.6 ± 6.1 | 98.7 ± 6.7 |
50 | 101.4 ± 2.4 | 102.2 ± 4.9 | 99.8 ± 3.6 | ||
OTα | 1 | 89.6 ± 2.9 | 88.3 ± 7.9 | 87.9 ± 8.1 | |
50 | 98.5 ± 7.0 | 93.6 ± 4.6 | 92.3 ± 4.8 | ||
Plasma | OTA | 1 | 86.0 ± 7.8 | 113.6 ± 2.8 | 93.4 ± 7.4 |
50 | 90.7 ± 11.8 | 93.2 ± 7.3 | 86.7 ± 6.7 | ||
OTα | 1 | 96.2 ± 11.7 | 94.7 ± 8.5 | 96.9 ± 7.8 | |
50 | 88.6 ± 5.5 | 96.7 ± 9.3 | 94.4 ± 4.6 | ||
Heart | OTA | 1 | 90.5 ± 8.6 | 95.3 ± 8.6 | 91.1 ± 5.1 |
50 | 85.8 ± 7.1 | 91.3 ± 9.1 | 99.0 ± 11.9 | ||
OTα | 1 | 99.0 ± 8.4 | 86.3 ± 10.4 | 95.5 ± 12.4 | |
50 | 91.3 ± 11.6 | 90.8 ± 7.2 | 97.1 ± 8.6 | ||
Liver | OTA | 1 | 91.0 ± 9.4 | 98.0 ± 10.1 | 93.5 ± 9.5 |
50 | 90.5 ± 8.2 | 94.2 ± 10.0 | 92.1 ± 10.3 | ||
OTα | 1 | 92.4 ± 7.2 | 92.6 ± 10.4 | 98.3 ± 9.4 | |
50 | 95.3 ± 8.5 | 93.3 ± 6.8 | 98.9 ± 9.6 | ||
Spleen | OTA | 1 | 87.7 ± 12.3 | 84.3 ± 6.1 | 90.0 ± 9.9 |
50 | 96.8 ± 10.1 | 88.8 ± 5.1 | 97.9 ± 5.5 | ||
OTα | 1 | 92.0 ± 12.6 | 96.2 ± 12.1 | 83.0 ± 5.1 | |
50 | 94.4 ± 6.1 | 98.5 ± 9.8 | 92.5 ± 9.4 | ||
Lung | OTA | 1 | 86.1 ± 8.1 | 92.9 ± 9.7 | 93.3 ± 9.8 |
50 | 90.9 ± 7.7 | 97.0 ± 11.4 | 85.1 ± 3.9 | ||
OTα | 1 | 89.6 ± 8.2 | 94.4 ± 10.9 | 98.1 ± 8.3 | |
50 | 93.7 ± 9.8 | 96.9 ± 10.2 | 85.3 ± 10.8 | ||
Kidney | OTA | 1 | 87.8 ± 9.4 | 87.3 ± 9.1 | 93.8 ± 6.0 |
50 | 100.4 ± 7.4 | 86.6 ± 8.7 | 90.6 ± 10.0 | ||
OTαα | 1 | 89.3 ± 9.7 | 97.2 ± 8.1 | 92.7 ± 9.7 | |
50 | 98.2 ± 8.3 | 91.8 ± 8.9 | 99.0 ± 6.0 |
The short-term, the freeze-thaw and long-term stabilities of OTA and OTα were assessed by comparing the concentrations of OTA and OTα in the spiked samples stored at different conditions with those in the freshly prepared samples: “a”: stored at room temperature (RT) for 8 h; “b”: subjected to three freeze-thaw cycles; “c”: stored at −20 °C for 20 days.